CTCM-226

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCTCM-226
Drug Alias Namediabetes therapy (Chemokine Therapeutics)CTCM-226
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunomodulatorsChemokine modulators
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesChemokine Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChemokine Therapeutics Corp
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A